216 related articles for article (PubMed ID: 33290900)
21. [Prognostic factors of bone and soft tissue sarcomas].
Furuse K
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2050-5. PubMed ID: 3293534
[TBL] [Abstract][Full Text] [Related]
22. The miR-34a-5p promotes the multi-chemoresistance of osteosarcoma via repression of the AGTR1 gene.
Pu Y; Zhao F; Li Y; Cui M; Wang H; Meng X; Cai S
BMC Cancer; 2017 Jan; 17(1):45. PubMed ID: 28073349
[TBL] [Abstract][Full Text] [Related]
23. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
24. MAFB Promotes Cancer Stemness and Tumorigenesis in Osteosarcoma through a Sox9-Mediated Positive Feedback Loop.
Chen Y; Wang T; Huang M; Liu Q; Hu C; Wang B; Han D; Chen C; Zhang J; Li Z; Liu C; Lei W; Chang Y; Wu M; Xiang D; Chen Y; Wang R; Huang W; Lei Z; Chu X
Cancer Res; 2020 Jun; 80(12):2472-2483. PubMed ID: 32234710
[TBL] [Abstract][Full Text] [Related]
25. Aberrant Wnt/β-catenin signaling and elevated expression of stem cell proteins are associated with osteosarcoma side population cells of high tumorigenicity.
Yi XJ; Zhao YH; Qiao LX; Jin CL; Tian J; Li QS
Mol Med Rep; 2015 Oct; 12(4):5042-8. PubMed ID: 26134785
[TBL] [Abstract][Full Text] [Related]
26. MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.
Fenger JM; Roberts RD; Iwenofu OH; Bear MD; Zhang X; Couto JI; Modiano JF; Kisseberth WC; London CA
BMC Cancer; 2016 Oct; 16(1):784. PubMed ID: 27724924
[TBL] [Abstract][Full Text] [Related]
27. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
28. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
29. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
30. [Prediction of the metastatic potential of sarcomas on the basis of a gene expression signature related to genome complexity].
Chibon F
Med Sci (Paris); 2011 Jan; 27(1):22-4. PubMed ID: 21299955
[No Abstract] [Full Text] [Related]
31. Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis.
Li YJ; Dai YL; Zhang WB; Li SJ; Tu CQ
Clin Exp Med; 2017 Feb; 17(1):59-69. PubMed ID: 26678086
[TBL] [Abstract][Full Text] [Related]
32. Endosialin‑expressing bone sarcoma stem‑like cells are highly tumor‑initiating and invasive.
Sun DX; Liao GJ; Liu KG; Jian H
Mol Med Rep; 2015 Oct; 12(4):5665-70. PubMed ID: 26300407
[TBL] [Abstract][Full Text] [Related]
33. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
[TBL] [Abstract][Full Text] [Related]
34. Fifty years of advances in sarcoma treatment: moving the needle from conventional chemotherapy to targeted therapy.
Patel SR
Am Soc Clin Oncol Educ Book; 2014; ():259-62. PubMed ID: 24857084
[TBL] [Abstract][Full Text] [Related]
35. Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.
Hu Y; Gu J; Shen H; Shao T; Li S; Wang W; Yu Z
J Clin Lab Anal; 2020 Feb; 34(2):e23045. PubMed ID: 31642110
[TBL] [Abstract][Full Text] [Related]
36. [Chemotherapy of advanced bone and soft tissue sarcoma].
Yamawaki S; Isu K; Ubayama Y; Yamaguti H; Gotou M
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1757-63. PubMed ID: 6541020
[TBL] [Abstract][Full Text] [Related]
37. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
[TBL] [Abstract][Full Text] [Related]
38. Soft tissue sarcomas: From a morphological to a molecular biological approach.
Oda Y; Yamamoto H; Kohashi K; Yamada Y; Iura K; Ishii T; Maekawa A; Bekki H
Pathol Int; 2017 Sep; 67(9):435-446. PubMed ID: 28759137
[TBL] [Abstract][Full Text] [Related]
39. Gene expression profiles for an immunoscore model in bone and soft tissue sarcoma.
Fan J; Qin X; He R; Ma J; Wei Q
Aging (Albany NY); 2021 May; 13(10):13708-13725. PubMed ID: 33946044
[TBL] [Abstract][Full Text] [Related]
40. Soft-tissue and bone sarcomas.
Scurr M; Judson I
Cancer Chemother Biol Response Modif; 2005; 22():591-604. PubMed ID: 16110630
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
